JP2023517934A5 - - Google Patents

Info

Publication number
JP2023517934A5
JP2023517934A5 JP2022554473A JP2022554473A JP2023517934A5 JP 2023517934 A5 JP2023517934 A5 JP 2023517934A5 JP 2022554473 A JP2022554473 A JP 2022554473A JP 2022554473 A JP2022554473 A JP 2022554473A JP 2023517934 A5 JP2023517934 A5 JP 2023517934A5
Authority
JP
Japan
Prior art keywords
viral vector
gene therapy
transgene
col4a4
col4a5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022554473A
Other languages
English (en)
Japanese (ja)
Other versions
JP7884456B2 (ja
JP2023517934A (ja
Filing date
Publication date
Priority claimed from GBGB2003618.2A external-priority patent/GB202003618D0/en
Application filed filed Critical
Publication of JP2023517934A publication Critical patent/JP2023517934A/ja
Publication of JP2023517934A5 publication Critical patent/JP2023517934A5/ja
Priority to JP2026037543A priority Critical patent/JP2026116914A/ja
Application granted granted Critical
Publication of JP7884456B2 publication Critical patent/JP7884456B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022554473A 2020-03-12 2021-03-12 遺伝子治療 Active JP7884456B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026037543A JP2026116914A (ja) 2020-03-12 2026-03-10 遺伝子治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2003618.2 2020-03-12
GBGB2003618.2A GB202003618D0 (en) 2020-03-12 2020-03-12 Gene Therapy
PCT/GB2021/050633 WO2021181118A1 (en) 2020-03-12 2021-03-12 Gene therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026037543A Division JP2026116914A (ja) 2020-03-12 2026-03-10 遺伝子治療

Publications (3)

Publication Number Publication Date
JP2023517934A JP2023517934A (ja) 2023-04-27
JP2023517934A5 true JP2023517934A5 (cg-RX-API-DMAC7.html) 2024-03-21
JP7884456B2 JP7884456B2 (ja) 2026-07-03

Family

ID=70453740

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554473A Active JP7884456B2 (ja) 2020-03-12 2021-03-12 遺伝子治療
JP2026037543A Pending JP2026116914A (ja) 2020-03-12 2026-03-10 遺伝子治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026037543A Pending JP2026116914A (ja) 2020-03-12 2026-03-10 遺伝子治療

Country Status (11)

Country Link
US (1) US12589167B2 (cg-RX-API-DMAC7.html)
EP (1) EP4118216A1 (cg-RX-API-DMAC7.html)
JP (2) JP7884456B2 (cg-RX-API-DMAC7.html)
CN (2) CN121950927A (cg-RX-API-DMAC7.html)
AU (1) AU2021234169B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022018036A2 (cg-RX-API-DMAC7.html)
CA (1) CA3171232A1 (cg-RX-API-DMAC7.html)
GB (1) GB202003618D0 (cg-RX-API-DMAC7.html)
IL (1) IL296255A (cg-RX-API-DMAC7.html)
MX (1) MX2022011295A (cg-RX-API-DMAC7.html)
WO (1) WO2021181118A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
EP4273243A1 (en) 2022-05-02 2023-11-08 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Nucleic acid constructs and vectors for podocyte specific expression
GB202304841D0 (en) * 2023-03-31 2023-05-17 Purespring Therapeutics Ltd Promoter
CN116590345B (zh) * 2023-05-06 2024-01-30 北京中医药大学 永生化小鼠足细胞系及其制备方法、分化方法和应用
GB202309908D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases
GB202309913D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Polynucleotides, avv vectors, and pharmaceutical compositions for treating nephrotic syndrome
GB202309914D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Promoters
GB202309909D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Regulatory elements
AU2025218305A1 (en) * 2024-02-07 2026-07-30 Purespring Therapeutics Limited Vectors
WO2025193938A1 (en) * 2024-03-13 2025-09-18 Oregon Health & Science University Delivery of type iv collagen alpha chain using a split intein dual aav vector

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
US20060281090A1 (en) 2003-05-01 2006-12-14 University Of Washington Uw Tech Transfer- Invention Licensing Capsid-modified adenovirus vectors and methods of using the same
US20050169914A1 (en) 2003-08-01 2005-08-04 Colgan Sean P. Novel functions for decay accelerating factor (DAF) in inflammation
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
KR101105125B1 (ko) 2007-05-07 2012-01-16 울산대학교 산학협력단 클러스터린을 이용한 체중 조절 장애 관련 질환의 진단, 예방 또는 치료 방법
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
CN108531444A (zh) 2010-08-05 2018-09-14 威斯康星校友研究基金会 用于人多能细胞培养的简化基础培养基
US8852936B2 (en) 2012-09-21 2014-10-07 Laurantis Pharma Oy Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
TW201506036A (zh) 2013-08-14 2015-02-16 Laurantis Pharma Oy Vegf-c及ccbe1之治療用途
JP2017532365A (ja) 2014-07-25 2017-11-02 ゴールドフィンチ バイオファーマ,インク. コラーゲンivの置き換え
KR20190075964A (ko) * 2016-10-13 2019-07-01 유니버시티 오브 매사추세츠 Aav 캡시드 설계
CN107011424B (zh) 2017-03-14 2020-07-03 华南师范大学 斜带石斑鱼补体c1inh基因、载体、重组菌株和蛋白及其应用
GB201706808D0 (en) 2017-04-28 2017-06-14 Univ Newcastle Modified complement proteins and uses thereof
EP3635121A1 (en) 2017-06-02 2020-04-15 Institut National de la Sante et de la Recherche Medicale (INSERM) Viral vector combining gene therapy and genome editing approaches for gene therapy of genetic disorders
CN111788311A (zh) 2017-10-20 2020-10-16 双子治疗公司 用于治疗年龄相关性黄斑变性的组合物和方法
RU2675861C1 (ru) 2017-11-22 2018-12-25 Лев Иосифович Шагам Способ прогнозирования наличия мутации гена col4a5 у пациентов с предполагаемым диагнозом "синдром альпорта"
SG11202100935TA (en) * 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
CN113166208B (zh) * 2018-10-02 2024-11-22 沃雅戈治疗公司 重新定向aav衣壳的嗜性
CA3117551A1 (en) 2018-10-23 2020-04-30 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
RU2714763C1 (ru) 2018-11-08 2020-02-19 Генетик Диагностикс Энд Терапи 21 Лтд Генотерапевтический ДНК-вектор для таргетной генной терапии, способ его получения (варианты), штамм для его производства, способ его получения
GB201900702D0 (en) 2019-01-18 2019-03-06 Univ Bristol Therapy
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
GB202010009D0 (en) 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
GB202103470D0 (en) 2021-03-12 2021-04-28 Univ Bristol Promoter

Similar Documents

Publication Publication Date Title
JP2022517407A5 (cg-RX-API-DMAC7.html)
FI3717636T3 (fi) Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
Murphy et al. Gene therapy for haemophilia
JP2019194251A5 (cg-RX-API-DMAC7.html)
SE504074C2 (sv) Proteinberedning för subkutan, intramuskulär eller intradermal administrering
JP2020203894A5 (cg-RX-API-DMAC7.html)
JP2020519292A5 (cg-RX-API-DMAC7.html)
JP2021503914A5 (cg-RX-API-DMAC7.html)
George et al. Gene therapy for hemophilia: past, present and future
FI3906066T3 (fi) Geeniterapiakonstrukteja wilsonin taudin hoitamiseksi
JP2022516317A5 (cg-RX-API-DMAC7.html)
JP2018527941A5 (cg-RX-API-DMAC7.html)
RU2018114907A (ru) Композиция и способ для лечения заболевания, опосредованного комплементом
JP2023503850A5 (cg-RX-API-DMAC7.html)
JP2004501650A5 (cg-RX-API-DMAC7.html)
Vance et al. AAV Biology, Infectivity and Therapeutic Use from
JP2025090820A5 (cg-RX-API-DMAC7.html)
Gruntman et al. Bridging from intramuscular to limb perfusion delivery of rAAV: optimization in a non-human primate study
JP2021500880A5 (cg-RX-API-DMAC7.html)
JP2023510784A5 (cg-RX-API-DMAC7.html)
JP2023534293A5 (cg-RX-API-DMAC7.html)
JPWO2022186282A5 (cg-RX-API-DMAC7.html)
Barbour The balance of risk and benefit in gene-therapy trials
JP2017530128A (ja) 肝細胞増殖因子及びストローマ細胞由来因子1αを用いた末梢動脈疾患の予防または治療用組成物
Karimipoor Recent advances in hemophilia gene therapy